Source notes

What makes a randomized trial convincing evidence that a treatment caused a change? Assigning participants by chance helps reduce differences between comparison groups, including differences researchers have not measured. But the control treatment, outcome definition, follow-up and analysis still matter. The authors explain these choices across several trial designs. They describe a conventional false-positive error rate of 5%: under the statistical assumptions, a procedure can wrongly declare a difference in about one of twenty repetitions when no true difference exists. This is not the probability that a particular published finding is false.

Randomization improves causal inference, but it does not guarantee perfectly balanced groups in every trial, especially small ones. Nor does it automatically make results applicable to everyone with a condition. Strict eligibility rules may exclude people who would use a treatment in practice. Blinding, where participants or assessors do not know the assignment, addresses another problem: expectations can influence reported outcomes or care.

How Does This Show Up in Real Life?

When reading that a treatment was tested in a randomized trial, look beyond that label. What was it compared with, and did the main outcome measure something that matters to patients? A change in a blood marker is not automatically evidence of longer life or better daily functioning. Check who entered the study and whether the follow-up was long enough for the outcome being claimed. The paper also explains why excluding people who stopped treatment can distort a comparison: their reasons for stopping may be related to outcomes. An intention-to-treat analysis retains the original assigned groups. These questions help readers judge a claim's scope without needing to reproduce the statistics. They also make a well-planned main result distinguishable from an interesting subgroup finding discovered after the data were examined.

This article explains methods rather than estimating how often trials succeed or fail. It illustrates choices with examples, not a pooled assessment of treatment benefits. Even strong trials can be costly, difficult to conduct and limited by missing data or an unusually selected population. Multiple outcomes and unplanned subgroup analyses also increase the opportunity for misleading positive findings.

Use this paper as a framework for reading clinical evidence with attention to design and interpretation. A randomized comparison deserves serious consideration, but the strength of a practical conclusion still depends on what was measured, how it was analysed and whom the results represent.